A Comparative Evaluation of Allogenic Cancellous Particulate Chips and Autologous Bone Graft From Symphysis in the Regeneration of Periodontal Intrabony Defect: A Randomized Controlled Clinico-Radiographic Study.

Background and objective Periodontal therapy primarily aims to regenerate periodontal supporting tissues lost due to periodontitis. Autogenous bone grafts (ABG) are viewed as the gold standard method in bone regeneration and they have fewer drawbacks. Hence, many different bone-regenerating materials can be used including allografts, which have excellent biological qualities.

Comparative Effectiveness of Biologic Classes in Clinical Practice: Month 12 Outcomes from the International Observational Psoriasis Study of Health Outcomes (PSoHO).

Introduction: Studies directly comparing the effectiveness of different biologics over long observation periods are lacking. As many treatment guidelines are formulated based on drug class, there is a particular need to compare drug classes rather than specific biologic agents.

Methods: This post hoc analysis compares the effectiveness and durability of biologics that target the interleukin (IL)-17 A ligands or the IL-17 receptor A (IL-17RA) relative to other approved drug classes in patients with moderate-to-severe plaque psoriasis, through 12 months in a real-world setting.

Patients with Persistent Mild Psoriasis after Treatment with Ustekinumab Achieved Greater Improvements in Skin Clearance and Patient-reported Outcomes after Switching to Guselkumab in the Phase 3 NAVIGATE Trial.

Mild psoriasis may be burdensome; if symptoms are inadequately controlled, switching therapy may be warranted. In the Phase 3 NAVIGATE trial, patients with moderate-to-severe plaque psoriasis received ustekinumab for 16 weeks. Patients with inadequate response (Investigator's Global Assessment [IGA] ≥ 2) were randomized to switch to guselkumab or continue ustekinumab.